Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, et al
Several important considerations apply: Individuals with active or severe gastrointestinal disease may experience worsening symptoms due to the gastrointestinal side effects of GLP-1 medications The slowed gastric emptying caused by these drugs could theoretically exacerbate symptoms in people with strictures or obstructive complications of Crohn's disease Weight loss associated with GLP-1 therapy may be inappropriate in patients with Crohn's disease who are already experiencing malnutrition or unintentional weight loss The interaction between GLP-1 medications and the inflammatory processes in IBD is not fully understood Clinical decision-making should involve a thorough assessment of disease activity, nutritional status, presence of complications (such as strictures or fistulas), and the primary indication for GLP-1 therapy
How is FormBlends different from other peptide suppliers
Reta Peptide: What Is It Really
Cmo Incorporar la L-Carnitina en la Dieta Fuentes Alimenticias Aunque la suplementacin con L-carnitina es una forma comn de aumentar su ingesta, tambin se puede obtener a travs de la dieta
